Symbols / OPK Stock $1.23 +0.82% OPKO Health, Inc.

Healthcare • Diagnostics & Research • United States • NMS
OPK (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Diagnostics & Research
CEO Dr. Phillip Frost M.D., Ph.D.
Exch · Country NMS · United States
Market Cap 944.27M
Enterprise Value 966.03M
Income -225.68M
Sales 606.88M
FCF (ttm) -131.25M
Book/sh 1.67
Cash/sh 0.48
Employees 2,275
Insider 10d —
IPO Nov 02, 1995
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.73
PEG 93.65
P/S 1.56
P/B 0.74
P/C —
EV/EBITDA -7.58
EV/Sales 1.59
Quick Ratio 3.21
Current Ratio 3.97
Debt/Eq 31.29
LT Debt/Eq —
EPS (ttm) -0.30
EPS next Y -0.33
EPS Growth —
Revenue Growth -19.20%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-04-28
Earnings (prior) 2026-02-26
ROA -6.62%
ROE -17.14%
ROIC —
Gross Margin 13.50%
Oper. Margin -28.98%
Profit Margin -37.19%
Shs Outstand 759.07M
Shs Float 336.30M
Insider Own 49.35%
Instit Own 27.02%
Short Float 7.65%
Short Ratio 13.00
Short Interest 32.98M
52W High 1.60
vs 52W High -23.13%
52W Low 1.10
vs 52W Low 11.82%
Beta 1.49
Impl. Vol. 12.50%
Rel Volume 0.73
Avg Volume 2.50M
Volume 1.82M
Target (mean) $3.40
Tgt Median $3.00
Tgt Low $1.40
Tgt High $8.50
# Analysts 6
Recom None
Prev Close $1.22
Price $1.23
Change 0.82%
About

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$3.40
Mean price target
2. Current target
$1.23
Latest analyst target
3. DCF / Fair value
$-3.11
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.23
Low
$1.40
High
$8.50
Mean
$3.40

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-02 main Barrington Research Outperform → Outperform $2
2025-11-20 init JP Morgan — → Neutral —
2025-10-31 down Jefferies Buy → Hold $2
2025-10-30 main Barrington Research Outperform → Outperform $2
2025-05-01 main Barrington Research Outperform → Outperform $2
2025-04-25 init JP Morgan — → Neutral —
2025-04-07 reit HC Wainwright & Co. Buy → Buy $3
2025-03-19 reit HC Wainwright & Co. Buy → Buy $3
2025-03-12 reit HC Wainwright & Co. Buy → Buy $3
2025-03-12 main Barrington Research Outperform → Outperform $2
2025-03-03 reit HC Wainwright & Co. Buy → Buy $3
2025-02-28 main Barrington Research Outperform → Outperform $2
2025-01-08 main HC Wainwright & Co. Buy → Buy $3
2024-11-08 main Barrington Research Outperform → Outperform $2
2024-09-26 reit HC Wainwright & Co. Buy → Buy $3
2024-09-20 main Barrington Research Outperform → Outperform $2
2024-09-17 reit Piper Sandler Overweight → Overweight $3
2024-09-17 reit HC Wainwright & Co. Buy → Buy $3
2024-08-08 main Barrington Research Outperform → Outperform $2
2024-07-18 main Piper Sandler Overweight → Overweight $3
News
RSS: Latest OPK news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-20 PAGANELLI JOHN A Director — 10,000 $1.14 $11,350
2025-11-21 FROST PHILLIP MD ET AL Chief Executive Officer — 580,000 $1.30 $768,807
2025-11-20 FROST PHILLIP MD ET AL Beneficial Owner of more than 10% of a Class of Security — 580,000 $1.32 $771,328
2025-11-19 FROST PHILLIP MD ET AL Chief Executive Officer — 580,000 $1.28 $759,115
2025-11-18 FROST PHILLIP MD ET AL Beneficial Owner of more than 10% of a Class of Security — 46,700 $1.26 $58,842
2025-11-18 FROST PHILLIP MD ET AL Beneficial Owner of more than 10% of a Class of Security — 533,300 $1.24 $678,906
2025-10-31 FROST PHILLIP MD ET AL Beneficial Owner of more than 10% of a Class of Security — 150,000 $1.42 $213,435
2025-08-18 FROST PHILLIP MD ET AL Beneficial Owner of more than 10% of a Class of Security — 440,000 $0.00 $0
2025-08-08 FROST PHILLIP MD ET AL Chief Executive Officer — 675,000 $1.32 $891,000
2025-04-08 FROST PHILLIP MD ET AL Beneficial Owner of more than 10% of a Class of Security — 125,000 $1.48 $184,650
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
606.88
-14.90%
713.14
-17.41%
863.50
-14.01%
1,004.20
Operating Revenue
606.88
-14.90%
713.14
-17.41%
863.50
-14.01%
1,004.20
Cost Of Revenue
400.94
-18.94%
494.63
-9.30%
545.37
-23.83%
715.98
Reconciled Cost Of Revenue
387.20
-19.18%
479.09
-8.94%
526.10
-24.31%
695.11
Gross Profit
205.94
-5.75%
218.51
-31.31%
318.13
+10.38%
288.22
Operating Expense
424.93
-13.65%
492.07
+3.34%
476.18
-10.88%
534.34
Research And Development
124.03
+17.89%
105.21
+17.44%
89.59
+21.26%
73.89
Selling General And Administration
223.00
-26.70%
304.22
+1.22%
300.56
-19.35%
372.67
Total Expenses
825.86
-16.30%
986.70
-3.41%
1,021.55
-18.30%
1,250.32
Total Operating Income As Reported
-117.41
+22.79%
-152.06
+3.16%
-157.02
+30.60%
-226.25
EBITDA
-41.27
-130.51%
135.28
+306.48%
-65.52
+75.81%
-270.81
Normalized EBITDA
-142.42
-456.53%
39.95
+160.74%
-65.77
+77.42%
-291.33
Reconciled Depreciation
91.63
-6.67%
98.18
-6.76%
105.30
-3.09%
108.66
EBIT
-132.90
-458.20%
37.10
+121.72%
-170.81
+54.99%
-379.46
Total Unusual Items
101.15
+6.10%
95.33
+37285.10%
0.26
-98.76%
20.52
Total Unusual Items Excluding Goodwill
101.15
+6.10%
95.33
+37285.10%
0.26
-98.76%
20.52
Special Income Charges
101.58
-16.39%
121.49
+11627.12%
1.04
-94.79%
19.87
Restructuring And Mergern Acquisition
0.00
0.00
+100.00%
-1.04
+21.04%
-1.31
Write Off
—
—
—
—
Net Income
-225.68
-324.02%
-53.22
+71.82%
-188.86
+42.49%
-328.40
Pretax Income
-241.36
-2229.32%
-10.36
+94.38%
-184.32
+52.92%
-391.52
Net Non Operating Interest Income Expense
-93.65
-139.89%
-39.04
-309.94%
-9.52
+5.48%
-10.07
Interest Expense Non Operating
108.46
+128.51%
47.47
+251.44%
13.51
+12.03%
12.06
Net Interest Income
-93.65
-139.89%
-39.04
-309.94%
-9.52
+5.48%
-10.07
Interest Expense
108.46
+128.51%
47.47
+251.44%
13.51
+12.03%
12.06
Interest Income Non Operating
14.81
+75.78%
8.43
+111.55%
3.98
+101.06%
1.98
Interest Income
14.81
+75.78%
8.43
+111.55%
3.98
+101.06%
1.98
Other Income Expense
71.27
-76.42%
302.24
+1905.57%
-16.74
+87.63%
-135.32
Other Non Operating Income Expenses
-29.88
-114.44%
206.90
+1317.51%
-16.99
+89.10%
-155.84
Gain On Sale Of Security
-0.43
+98.36%
-26.16
-3249.68%
-0.78
-220.34%
0.65
Tax Provision
-15.71
-136.67%
42.84
+865.61%
4.44
+106.99%
-63.50
Tax Rate For Calcs
0.00
-69.00%
0.00
+0.00%
0.00
+29.63%
0.00
Tax Effect Of Unusual Items
6.58
-67.11%
20.02
+37285.10%
0.05
-98.39%
3.32
Net Income Including Noncontrolling Interests
-225.68
-324.02%
-53.22
+71.82%
-188.86
+42.49%
-328.40
Net Income From Continuing Operation Net Minority Interest
-225.68
-324.02%
-53.22
+71.82%
-188.86
+42.49%
-328.40
Net Income From Continuing And Discontinued Operation
-225.68
-324.02%
-53.22
+71.82%
-188.86
+42.49%
-328.40
Net Income Continuous Operations
-225.68
-324.02%
-53.22
+71.82%
-188.86
+42.49%
-328.40
Normalized Income
-320.24
-149.15%
-128.54
+32.01%
-189.06
+45.29%
-345.60
Net Income Common Stockholders
-225.68
-324.02%
-53.22
+71.82%
-188.86
+42.49%
-328.40
Diluted EPS
-0.30
-275.00%
-0.08
+68.00%
-0.25
+45.65%
-0.46
Basic EPS
-0.30
-275.00%
-0.08
+68.00%
-0.25
+45.65%
-0.46
Basic Average Shares
751.13
+8.23%
694.02
-7.68%
751.72
+4.54%
719.06
Diluted Average Shares
751.13
+8.23%
694.02
-7.68%
751.72
+4.54%
719.06
Diluted NI Availto Com Stockholders
-225.68
-324.02%
-53.22
+71.82%
-188.86
+42.49%
-328.40
Amortization
77.89
-5.74%
82.63
-3.95%
86.03
-2.00%
87.78
Amortization Of Intangibles Income Statement
77.89
-5.74%
82.63
-3.95%
86.03
-2.00%
87.78
Depreciation Amortization Depletion Income Statement
77.89
-5.74%
82.63
-3.95%
86.03
-2.00%
87.78
Depreciation And Amortization In Income Statement
77.89
-5.74%
82.63
-3.95%
86.03
-2.00%
87.78
Earnings From Equity Interest Net Of Tax
-0.03
-61.11%
-0.02
+83.18%
-0.11
+72.06%
-0.38
Gain On Sale Of PPE
101.58
-16.39%
121.49
0.00
-100.00%
18.56
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,931.94
-12.19%
2,200.21
+9.37%
2,011.70
-7.18%
2,167.26
Current Assets
581.88
-12.11%
662.09
+113.94%
309.48
-21.56%
394.52
Cash Cash Equivalents And Short Term Investments
369.07
-14.55%
431.94
+350.49%
95.88
-37.41%
153.19
Cash And Cash Equivalents
369.07
-14.55%
431.94
+350.49%
95.88
-37.41%
153.19
Receivables
126.12
-17.05%
152.05
+16.78%
130.20
-12.39%
148.61
Accounts Receivable
90.25
-23.52%
118.02
-4.35%
123.38
-3.09%
127.31
Gross Accounts Receivable
92.33
-22.60%
119.28
-4.86%
125.38
-4.64%
131.47
Allowance For Doubtful Accounts Receivable
-2.07
-63.38%
-1.27
+36.65%
-2.00
+51.95%
-4.16
Other Receivables
24.02
-6.77%
25.77
+887.16%
2.61
-80.08%
13.11
Taxes Receivable
11.84
+43.26%
8.27
+96.30%
4.21
-48.59%
8.19
Inventory
65.82
+15.89%
56.80
-13.55%
65.70
-11.29%
74.06
Raw Materials
24.62
-1.15%
24.91
-28.52%
34.84
-8.41%
38.05
Work In Process
0.73
-69.17%
2.35
+36.05%
1.73
-29.32%
2.45
Finished Goods
43.99
+36.16%
32.31
-9.20%
35.58
-4.19%
37.14
Prepaid Assets
12.70
+19.77%
10.60
+5.77%
10.03
-19.24%
12.41
Assets Held For Sale Current
—
—
—
0.00
Other Current Assets
8.17
-23.70%
10.71
+39.52%
7.67
+22.73%
6.25
Total Non Current Assets
1,350.06
-12.23%
1,538.12
-9.64%
1,702.22
-3.98%
1,772.73
Net PPE
120.86
-2.64%
124.14
-13.50%
143.52
+18.02%
121.60
Gross PPE
246.47
-6.23%
262.84
-12.58%
300.64
+13.88%
264.01
Accumulated Depreciation
-125.62
+9.43%
-138.70
+11.73%
-157.13
-10.34%
-142.41
Properties
0.00
0.00
0.00
0.00
Land And Improvements
2.54
+13.36%
2.24
-7.71%
2.42
+4.66%
2.32
Buildings And Improvements
15.57
+19.17%
13.06
-30.83%
18.89
+3.12%
18.31
Machinery Furniture Equipment
139.44
-9.08%
153.36
-13.81%
177.93
+2.06%
174.34
Construction In Progress
27.65
+43.78%
19.23
+265.90%
5.25
+9.64%
4.79
Other Properties
46.93
-13.10%
54.00
-20.69%
68.09
+75.82%
38.73
Leases
14.35
-31.46%
20.94
-25.36%
28.06
+9.96%
25.52
Goodwill And Other Intangible Assets
1,195.57
-10.84%
1,340.87
-12.56%
1,533.54
-5.01%
1,614.37
Goodwill
484.29
-8.50%
529.25
-11.53%
598.26
+0.40%
595.85
Other Intangible Assets
711.28
-12.36%
811.61
-13.22%
935.28
-8.17%
1,018.52
Investments And Advances
14.16
-74.05%
54.58
+239.43%
16.08
-42.68%
28.05
Long Term Equity Investment
0.76
-3.68%
0.79
-92.56%
10.58
-51.95%
22.02
Other Non Current Assets
19.47
+5.05%
18.54
+104.15%
9.08
+4.62%
8.68
Total Liabilities Net Minority Interest
663.99
-20.46%
834.76
+34.10%
622.48
+2.79%
605.61
Current Liabilities
146.68
-24.04%
193.10
-3.48%
200.05
-6.29%
213.48
Payables And Accrued Expenses
84.14
-31.40%
122.66
+3.46%
118.56
-2.98%
122.21
Payables
44.70
-35.54%
69.35
-2.41%
71.06
-1.77%
72.34
Accounts Payable
41.10
-12.68%
47.07
-32.44%
69.68
+4.01%
66.99
Current Accrued Expenses
39.45
-26.01%
53.32
+12.24%
47.50
-4.74%
49.87
Employee Benefits
5.54
-61.17%
14.27
0.00
—
Pensionand Other Post Retirement Benefit Plans Current
33.78
-1.14%
34.17
+18.01%
28.95
-14.25%
33.77
Total Tax Payable
3.60
-83.86%
22.27
+1509.47%
1.38
-74.14%
5.35
Current Debt And Capital Lease Obligation
22.86
-22.11%
29.35
-31.93%
43.12
-15.50%
51.03
Current Debt
10.25
-31.75%
15.02
-44.97%
27.29
-25.41%
36.59
Other Current Borrowings
10.25
-31.75%
15.02
-44.97%
27.29
-25.41%
36.59
Current Capital Lease Obligation
12.61
-12.01%
14.33
-9.45%
15.82
+9.60%
14.44
Current Deferred Liabilities
—
—
0.00
0.00
Current Deferred Revenue
—
—
0.00
0.00
Other Current Liabilities
—
—
—
—
Total Non Current Liabilities Net Minority Interest
517.31
-19.38%
641.67
+51.90%
422.43
+7.73%
392.13
Long Term Debt And Capital Lease Obligation
373.92
-21.30%
475.10
+67.61%
283.45
+11.37%
254.52
Long Term Debt
333.71
-20.96%
422.18
+90.14%
222.03
+1.17%
219.47
Long Term Capital Lease Obligation
40.21
-24.01%
52.91
-13.84%
61.41
+75.21%
35.05
Non Current Pension And Other Postretirement Benefit Plans
5.54
-61.17%
14.27
0.00
—
Non Current Deferred Liabilities
126.24
-10.34%
140.80
+11.06%
126.78
+0.17%
126.56
Non Current Deferred Revenue
—
0.01
-14.29%
0.01
-94.93%
0.14
Non Current Deferred Taxes Liabilities
126.24
-10.34%
140.80
+11.06%
126.77
+0.27%
126.43
Other Non Current Liabilities
11.60
+0.87%
11.50
-5.71%
12.20
+10.44%
11.05
Stockholders Equity
1,267.96
-7.14%
1,365.45
-1.71%
1,389.22
-11.04%
1,561.65
Common Stock Equity
1,267.96
-7.14%
1,365.45
-1.71%
1,389.22
-11.04%
1,561.65
Capital Stock
7.90
+12.62%
7.01
-10.29%
7.82
+0.09%
7.81
Common Stock
7.90
+12.62%
7.01
-10.29%
7.82
+0.09%
7.81
Share Issued
789.92
+12.63%
701.35
-10.31%
781.94
+0.08%
781.31
Ordinary Shares Number
759.07
+13.03%
671.55
-13.16%
773.28
+0.08%
772.65
Treasury Shares Number
30.85
+3.52%
29.80
+244.31%
8.66
+0.00%
8.66
Additional Paid In Capital
3,574.94
+2.69%
3,481.36
+1.41%
3,433.01
+0.33%
3,421.87
Retained Earnings
-2,290.69
-10.93%
-2,065.01
-2.65%
-2,011.79
-10.36%
-1,822.92
Gains Losses Not Affecting Retained Earnings
-21.02
+62.56%
-56.13
-47.59%
-38.03
+12.22%
-43.32
Treasury Stock
3.18
+77.33%
1.79
+0.00%
1.79
+0.00%
1.79
Other Equity Adjustments
-21.02
+62.56%
-56.13
-47.59%
-38.03
+12.22%
-43.32
Total Equity Gross Minority Interest
1,267.96
-7.14%
1,365.45
-1.71%
1,389.22
-11.04%
1,561.65
Total Capitalization
1,601.67
-10.40%
1,787.63
+10.95%
1,611.25
-9.54%
1,781.12
Working Capital
435.20
-7.20%
468.99
+328.60%
109.42
-39.56%
181.04
Invested Capital
1,611.92
-10.58%
1,802.65
+10.02%
1,638.55
-9.86%
1,817.71
Total Debt
396.78
-21.34%
504.44
+54.47%
326.56
+6.88%
305.55
Net Debt
—
5.27
-96.57%
153.45
+49.17%
102.87
Capital Lease Obligations
52.82
-21.45%
67.24
-12.94%
77.24
+56.07%
49.49
Net Tangible Assets
72.39
+194.49%
24.58
+117.03%
-144.32
-173.74%
-52.72
Available For Sale Securities
13.41
-75.08%
53.79
+878.43%
5.50
-8.81%
6.03
Current Provisions
5.90
-14.78%
6.92
-26.54%
9.42
+45.44%
6.48
Financial Assets
0.00
+0.00%
0.00
+50.00%
0.00
-92.86%
0.03
Interest Payable
5.44
-34.57%
8.31
—
—
Inventories Adjustments Allowances
-3.52
-26.75%
-2.77
+57.07%
-6.46
-80.78%
-3.57
Investmentin Financial Assets
13.41
-75.08%
53.79
+878.43%
5.50
-8.81%
6.03
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-178.54
+2.70%
-183.49
-550.74%
-28.20
+70.38%
-95.19
Cash Flow From Continuing Operating Activities
-178.54
+2.70%
-183.49
-550.74%
-28.20
+70.38%
-95.19
Net Income From Continuing Operations
-225.68
-324.02%
-53.22
+71.82%
-188.86
+42.49%
-328.40
Depreciation Amortization Depletion
91.63
-6.67%
98.18
-6.76%
105.30
-3.09%
108.66
Depreciation And Amortization
91.63
-6.67%
98.18
-6.76%
105.30
-3.09%
108.66
Other Non Cash Items
71.49
+454.49%
12.89
+339.13%
2.94
+12.97%
2.60
Stock Based Compensation
10.71
-3.02%
11.05
-3.20%
11.41
-38.34%
18.51
Asset Impairment Charge
1.01
0.00
0.00
—
Deferred Tax
-15.00
-201.73%
14.74
+9998.63%
0.15
+100.20%
-74.41
Deferred Income Tax
-15.00
-201.73%
14.74
+9998.63%
0.15
+100.20%
-74.41
Operating Gains Losses
-72.14
+60.98%
-184.87
-13046.22%
1.43
+107.66%
-18.63
Unrealized Gain Loss On Investment Securities
0.62
+100.54%
-114.43
-748.43%
17.65
-88.53%
153.84
Net Foreign Currency Exchange Gain Loss
—
—
—
—
Gain Loss On Sale Of PPE
-3.25
+94.88%
-63.40
-4899.17%
1.32
+390.33%
-0.46
Change In Working Capital
-41.18
-227.99%
32.17
+47.60%
21.80
-48.89%
42.65
Change In Receivables
30.21
+13833.18%
-0.22
-106.45%
3.41
-97.35%
128.60
Changes In Account Receivables
30.21
+13833.18%
-0.22
-106.45%
3.41
-97.35%
128.60
Change In Inventory
-4.12
-197.65%
4.22
-72.25%
15.20
+11.24%
13.66
Change In Payables And Accrued Expense
-62.06
-321.46%
28.02
+1157.80%
-2.65
+97.36%
-100.50
Change In Accrued Expense
-47.84
-198.27%
48.68
+988.86%
-5.48
+93.99%
-91.11
Change In Payable
-14.22
+31.19%
-20.66
-830.62%
2.83
+130.12%
-9.39
Change In Account Payable
-14.22
+31.19%
-20.66
-830.62%
2.83
+130.12%
-9.39
Change In Other Working Capital
0.18
-95.43%
3.90
+476.35%
-1.04
-143.73%
2.37
Change In Other Current Assets
-5.40
-44.23%
-3.74
-154.42%
6.88
+564.28%
-1.48
Investing Cash Flow
230.30
-34.61%
352.21
+2035.45%
-18.20
-119.99%
91.04
Cash Flow From Continuing Investing Activities
230.30
-34.61%
352.21
+2035.45%
-18.20
-119.99%
91.04
Net PPE Purchase And Sale
0.29
+18.60%
0.24
-91.08%
2.71
+39.06%
1.95
Sale Of PPE
0.29
+18.60%
0.24
-91.08%
2.71
+39.06%
1.95
Capital Expenditure
-12.28
+50.91%
-25.01
-53.67%
-16.27
+33.78%
-24.58
Capital Expenditure Reported
-12.28
+50.91%
-25.01
-53.67%
-16.27
+33.78%
-24.58
Net Investment Purchase And Sale
52.18
-68.68%
166.60
+45670.33%
0.36
-99.68%
115.42
Sale Of Investment
52.18
-68.68%
166.60
+45670.33%
0.36
-99.68%
115.42
Net Business Purchase And Sale
190.10
-9.64%
210.38
+4307.56%
-5.00
-184.41%
-1.76
Purchase Of Business
-7.67
0.00
+100.00%
-5.00
-184.41%
-1.76
Gain Loss On Sale Of Business
—
—
0.00
+100.00%
-18.56
Financing Cash Flow
-118.06
-164.10%
184.17
+1729.36%
-11.30
-149.21%
22.97
Cash Flow From Continuing Financing Activities
-118.06
-164.10%
184.17
+1729.36%
-11.30
-149.21%
22.97
Net Issuance Payments Of Debt
-70.76
-124.57%
287.98
+2710.66%
-11.03
-146.46%
23.75
Issuance Of Debt
33.03
-96.48%
939.43
+39.86%
671.68
-36.61%
1,059.52
Repayment Of Debt
-103.79
+84.07%
-651.45
+4.58%
-682.71
+34.09%
-1,035.77
Long Term Debt Issuance
33.03
-96.48%
939.43
+39.86%
671.68
-36.61%
1,059.52
Long Term Debt Payments
-103.79
+84.07%
-651.45
+4.58%
-682.71
+34.09%
-1,035.77
Net Long Term Debt Issuance
-70.76
-124.57%
287.98
+2710.66%
-11.03
-146.46%
23.75
Short Term Debt Issuance
—
—
—
—
Short Term Debt Payments
—
—
—
—
Net Short Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
-47.04
+47.86%
-90.22
0.00
0.00
Common Stock Payments
-47.04
+47.86%
-90.22
0.00
0.00
Repurchase Of Capital Stock
-47.04
+47.86%
-90.22
0.00
0.00
Proceeds From Stock Option Exercised
-0.26
-23.08%
-0.21
+23.53%
-0.27
+64.86%
-0.77
Net Other Financing Charges
—
-13.38
—
—
Changes In Cash
-66.30
-118.79%
352.89
+711.62%
-57.70
-406.58%
18.82
Effect Of Exchange Rate Changes
3.43
+208.62%
-3.16
-913.66%
0.39
+214.45%
-0.34
Beginning Cash Position
445.62
+364.76%
95.88
-37.41%
153.19
+13.72%
134.71
End Cash Position
382.74
-14.11%
445.62
+364.76%
95.88
-37.41%
153.19
Free Cash Flow
-190.82
+8.48%
-208.50
-368.83%
-44.47
+62.87%
-119.77
Interest Paid Supplemental Data
37.94
+81.66%
20.88
+156.71%
8.13
+9.64%
7.42
Income Tax Paid Supplemental Data
24.46
+144.43%
10.01
+169.61%
3.71
-53.81%
8.04
Common Stock Issuance
—
—
—
—
Earnings Losses From Equity Investments
0.03
+61.11%
0.02
-83.18%
0.11
-72.06%
0.38
Issuance Of Capital Stock
—
—
—
—
Sale Of Business
197.77
-5.99%
210.38
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category